Gujarat Kidney and Super Speciality Limited is a healthcare services company operating multi-speciality and super-speciality hospitals across Gujarat. The company earns revenue through inpatient and outpatient treatments, surgeries, diagnostics, pharmacy sales, and specialised medical procedures. Its core services include nephrology, urology, cardiology, oncology, orthopaedics, gynaecology, and tertiary care services delivered through hospital infrastructure and in-house pharmacies.

The Company is led by Promoter, i.e., DR. PRAGNESH YASHWANTSINH BHARPODA, DR. BHARTIBEN PRAGNESH BHARPODA, DR. YASHWANTSINGH MOTISINH BHARPODA AND ANITABEN YASHWANTSINH BHARPODA

The Revenues from operations for the Period ended on June 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 1,526.85 Lakh, ₹ 4,039.70 Lakh, â‚¹ 547.82 Lakh, and ₹ 0.01 Lakh, The EBITDA for the Period ended on June 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 862.56 Lakh, ₹ 1,654.70 Lakh, ₹ 195.09 Lakh, and ₹ -0.63 Lakh, The Profit after Tax for the Period ended on June 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were â‚¹ 540.32 Lakh, ₹ 949.94 Lakh, â‚¹ 171.40 Lakh, and ₹ -0.62 Lakh, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of â‚¹1.85 and post-issue EPS of ₹1.20 for FY25. The pre-issue P/E ratio is 61.62x,while the post-issue P/E ratio is 94.62x against the Industry P/E ratio is 44.34x The company's ROE for FY25 is 36.61% and RoNW is 36.61% The Annualised EPS is ₹2.74x and P/E is 41.59x. These metrics suggest that the IPO is Fully priced.

The Grey Market Premium (GMP) of Gujarat Kidney & Super Speciality showing listing gains of 0%.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Avoid to the Gujarat Kidney & Super Speciality Limited IPO for Listing gain or Long Term Purposes.